Home
REGENXBIO

REGENXBIO Market Share Analysis for June 2026

Health > Biotechnology and Pharmaceuticals

Domainregenxbio.com

Year Founded2008

Employees201 - 500

Annual Revenue$100M - $200M

REGENXBIO

REGENXBIO (including company regionals)

regenxbio.com

See more website traffic and engagement information

REGENXBIO Revenue up to June 2026 is 100M - 200M

revenue generated by REGENXBIO top domains

REGENXBIO top domains revenue over 3 years

Revenue for REGENXBIO top domains

regenxbio.com100M - 200M

See more with Sales Intelligence

Total visits to REGENXBIO's top domains

Understand REGENXBIO market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

regenxbio.com14.1K

See more with Sales Intelligence

Avg. visit duration in REGENXBIO's top domains

Analyze REGENXBIO engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

regenxbio.com00:00:21

See more with Sales Intelligence

Avg. pageviews on REGENXBIO's top domains

See how REGENXBIO keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

regenxbio.com1.85

See more with Sales Intelligence

REGENXBIO top competitors by domain

Top similar sites in June 2026, ranked by their affinity

askbio.comCompany NameAskBioEmployees501 - 1000HQUnited States, North Carolina, DurhamAnnual revenue$15M - $25MTotal visits16KHealth > Biotechnology and Pharmaceuticals

Top technologies used by REGENXBIO

These are the website technologies, by industry, used by REGENXBIO top domains

Widget (11)

Twemoji

Conversion & Analytics (3)

Google Analytics

Social (3)

Google+ Platform

Content Management System (2)

WordPress

More Technologies

10

See all

News & Signals from REGENXBIO

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsREGENXBIO Inc. is developing Navsunli on Jun 22nd '26.Regenxbio's Navsunli is being developed as a one-time gene therapy for Hunter syndrome, or MPS II, a rare inherited disorder that affects physical and cognitive development.

NewsBragar Eagel & Squire PC filed suit against REGENXBIO Inc. on Apr 3rd '26.NEW YORK, April 03, 2026 (GLOBE NEWSWIRE) - Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of PayPal Holdings, Inc. (NASDAQ:PYPL) and REGENXBIO Inc. (NASDAQ:RGNX).

NewsSchall Law Firm filed suit against REGENXBIO Inc. on Apr 13th '26.LOS ANGELES, March 19, 2026 (GLOBE NEWSWIRE) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against REGENXBIO Inc. ("Regenxbio" or "the Company") (NASDAQ: RGNX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.